Share Price and Basic Stock Data
Last Updated: January 7, 2026, 8:04 pm
| PEG Ratio | 1.34 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ambar Protein Industries Ltd operates in the edible oils and solvent extraction sector, demonstrating a notable revenue trajectory over the years. For the financial year ending March 2025, the company reported sales of ₹421 Cr, up from ₹336 Cr in March 2024, reflecting a growth trend that aligns with the rising demand for edible oils in India. Quarterly sales data shows variability, with the highest quarterly sales of ₹127.81 Cr recorded in March 2025, while the most recent quarter in September 2023 saw sales decline to ₹68.61 Cr. This fluctuation may be indicative of seasonal demand trends or competitive pressures within the sector. The company reported a trailing twelve months (TTM) revenue of ₹469 Cr, showcasing its ability to generate consistent sales, although the operating profit margin (OPM) stood at a modest 2.25%, suggesting room for improvement in cost management and pricing strategy. Overall, Ambar Protein’s revenue growth trajectory positions it favorably in a competitive market, although maintaining consistent sales will be critical for future performance.
Profitability and Efficiency Metrics
Ambar Protein Industries Ltd’s profitability metrics indicate a mixed performance, with a net profit of ₹10 Cr for the financial year ending March 2025. The net profit margin stood at 2.28%, which is relatively low compared to industry standards. This could be attributed to the company’s operating profit margin, which fluctuated between 0.92% and 4.76% in the past quarters, highlighting challenges in maintaining operational efficiency. The return on equity (ROE) is notably high at 27.79%, indicating effective utilization of shareholders’ funds, while the return on capital employed (ROCE) reached 41.06%, suggesting that the company is generating significant returns on its capital. However, the interest coverage ratio (ICR) of 7.32x indicates a healthy capacity to meet interest obligations, which is a positive sign for financial stability. The cash conversion cycle (CCC) of 34 days reveals a relatively efficient process in converting sales into cash, although improvements in inventory and debtor management could enhance this further.
Balance Sheet Strength and Financial Ratios
Ambar Protein’s balance sheet reflects a solid financial standing, with total assets amounting to ₹71 Cr as of March 2025, against total liabilities of ₹71 Cr, indicating a balanced financial structure. The company reported reserves of ₹32 Cr, which have consistently increased from ₹16 Cr in March 2023, suggesting improved retained earnings and financial prudence. Borrowings amounted to ₹23 Cr, down from ₹29 Cr in the previous year, indicating a reduction in debt and enhancing the company’s financial leverage. The long-term debt to equity ratio remains low at 0.00, highlighting minimal reliance on long-term debt financing. Financial ratios such as the current ratio of 1.45 and quick ratio of 0.83 suggest adequate liquidity to cover short-term obligations. However, the price-to-book value (P/BV) ratio of 3.36x indicates that the stock may be valued at a premium compared to its book value, necessitating scrutiny for potential investor returns.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ambar Protein Industries Ltd reveals a strong promoter backing, with promoters holding 71.48% of the equity as of September 2025, indicating a significant level of control and commitment to the company’s success. The public shareholding stood at 28.51%, reflecting a healthy distribution of shares among retail investors. Over the past year, the number of shareholders has increased to 3,177, demonstrating growing investor interest and confidence in the company. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may suggest an opportunity for future institutional interest, which could enhance stability and liquidity in the stock. The consistent promoter stake and rising shareholder base could be viewed positively by potential investors, as it signifies confidence in the company’s long-term prospects. However, the reliance on a concentrated promoter holding could pose risks if any adverse developments affect shareholder sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Ambar Protein Industries Ltd faces both opportunities and challenges. The increasing demand for edible oils in India presents a significant growth opportunity, especially as the company aims to enhance its operational efficiency and profitability. However, risks include potential fluctuations in raw material prices, which could impact margins, and increased competition from both domestic and international players. Additionally, the company’s relatively low net profit margin suggests a need for strategic initiatives to improve cost management. If Ambar Protein can leverage its strong market position and improve its operational efficiencies, it may be well-positioned for sustainable growth. Conversely, failure to adapt to market dynamics and manage costs could hinder future performance. Overall, Ambar Protein’s ability to navigate these challenges will be crucial to its long-term success and shareholder value creation.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modi Naturals Ltd | 473 Cr. | 355 | 610/320 | 13.0 | 107 | 0.00 % | 18.7 % | 29.2 % | 10.0 |
| IEL Ltd | 94.5 Cr. | 7.25 | 10.3/4.00 | 3.37 | 0.00 % | 2.51 % | 1.91 % | 1.00 | |
| Evexia Lifecare Ltd | 314 Cr. | 1.67 | 3.62/1.52 | 219 | 3.02 | 0.00 % | 0.30 % | 0.32 % | 1.00 |
| Diligent Industries Ltd | 68.7 Cr. | 2.88 | 3.95/1.45 | 26.7 | 2.79 | 0.00 % | 7.06 % | 6.09 % | 1.00 |
| CIAN Agro Industries & Infrastructure Ltd | 3,894 Cr. | 1,391 | 3,633/321 | 1,918 | 33.0 | 0.00 % | 8.54 % | 1.06 % | 10.0 |
| Industry Average | 10,632.64 Cr | 175.28 | 149.80 | 37.26 | 0.17% | 14.31% | 12.90% | 4.29 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 75.77 | 94.92 | 90.00 | 93.22 | 68.61 | 85.72 | 89.51 | 93.04 | 88.95 | 111.82 | 127.81 | 117.27 | 111.66 |
| Expenses | 74.30 | 92.42 | 89.17 | 90.62 | 67.04 | 81.90 | 90.26 | 90.10 | 84.72 | 107.00 | 124.02 | 115.13 | 109.15 |
| Operating Profit | 1.47 | 2.50 | 0.83 | 2.60 | 1.57 | 3.82 | -0.75 | 2.94 | 4.23 | 4.82 | 3.79 | 2.14 | 2.51 |
| OPM % | 1.94% | 2.63% | 0.92% | 2.79% | 2.29% | 4.46% | -0.84% | 3.16% | 4.76% | 4.31% | 2.97% | 1.82% | 2.25% |
| Other Income | 0.13 | 0.12 | 0.14 | 0.12 | 0.12 | 0.12 | 0.31 | 0.22 | 0.22 | 0.19 | 0.20 | 0.19 | 0.18 |
| Interest | 0.66 | 0.65 | 0.60 | 0.64 | 0.63 | 0.69 | 0.50 | 0.56 | 0.56 | 0.57 | 0.58 | 0.53 | 0.45 |
| Depreciation | 0.32 | 0.32 | 0.31 | 0.33 | 0.26 | 0.39 | 0.34 | 0.32 | 0.32 | 0.46 | 0.21 | 0.33 | 0.34 |
| Profit before tax | 0.62 | 1.65 | 0.06 | 1.75 | 0.80 | 2.86 | -1.28 | 2.28 | 3.57 | 3.98 | 3.20 | 1.47 | 1.90 |
| Tax % | 27.42% | 37.58% | 116.67% | 27.43% | 2.50% | 45.10% | -64.84% | 24.56% | 24.65% | 29.15% | 22.19% | 48.98% | -5.26% |
| Net Profit | 0.46 | 1.03 | -0.02 | 1.26 | 0.78 | 1.56 | -0.45 | 1.72 | 2.69 | 2.82 | 2.48 | 0.75 | 2.00 |
| EPS in Rs | 0.80 | 1.79 | -0.03 | 2.19 | 1.36 | 2.71 | -0.78 | 2.99 | 4.68 | 4.90 | 4.31 | 1.30 | 3.48 |
Last Updated: December 28, 2025, 5:29 am
Below is a detailed analysis of the quarterly data for Ambar Protein Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 111.66 Cr.. The value appears to be declining and may need further review. It has decreased from 117.27 Cr. (Jun 2025) to 111.66 Cr., marking a decrease of 5.61 Cr..
- For Expenses, as of Sep 2025, the value is 109.15 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 115.13 Cr. (Jun 2025) to 109.15 Cr., marking a decrease of 5.98 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.51 Cr.. The value appears strong and on an upward trend. It has increased from 2.14 Cr. (Jun 2025) to 2.51 Cr., marking an increase of 0.37 Cr..
- For OPM %, as of Sep 2025, the value is 2.25%. The value appears strong and on an upward trend. It has increased from 1.82% (Jun 2025) to 2.25%, marking an increase of 0.43%.
- For Other Income, as of Sep 2025, the value is 0.18 Cr.. The value appears to be declining and may need further review. It has decreased from 0.19 Cr. (Jun 2025) to 0.18 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Sep 2025, the value is 0.45 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.53 Cr. (Jun 2025) to 0.45 Cr., marking a decrease of 0.08 Cr..
- For Depreciation, as of Sep 2025, the value is 0.34 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.33 Cr. (Jun 2025) to 0.34 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.90 Cr.. The value appears strong and on an upward trend. It has increased from 1.47 Cr. (Jun 2025) to 1.90 Cr., marking an increase of 0.43 Cr..
- For Tax %, as of Sep 2025, the value is -5.26%. The value appears to be improving (decreasing) as expected. It has decreased from 48.98% (Jun 2025) to -5.26%, marking a decrease of 54.24%.
- For Net Profit, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.75 Cr. (Jun 2025) to 2.00 Cr., marking an increase of 1.25 Cr..
- For EPS in Rs, as of Sep 2025, the value is 3.48. The value appears strong and on an upward trend. It has increased from 1.30 (Jun 2025) to 3.48, marking an increase of 2.18.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:15 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 160 | 157 | 168 | 195 | 206 | 231 | 284 | 313 | 340 | 345 | 336 | 421 | 469 |
| Expenses | 159 | 155 | 167 | 193 | 203 | 227 | 278 | 305 | 330 | 338 | 328 | 406 | 455 |
| Operating Profit | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 8 | 9 | 7 | 7 | 16 | 13 |
| OPM % | 1% | 1% | 1% | 1% | 1% | 2% | 2% | 2% | 3% | 2% | 2% | 4% | 3% |
| Other Income | 0 | 1 | 0 | 1 | 1 | 0 | 0 | -0 | 1 | 0 | 0 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Depreciation | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 2 | 1 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 13 | 11 |
| Tax % | 0% | 0% | 36% | 2% | 27% | 28% | 55% | 13% | 25% | 29% | 24% | 26% | |
| Net Profit | 0 | 2 | 1 | 2 | 2 | 2 | 1 | 3 | 4 | 3 | 3 | 10 | 8 |
| EPS in Rs | 0.14 | 2.70 | 1.51 | 4.19 | 3.74 | 3.53 | 2.17 | 6.00 | 7.74 | 4.89 | 5.48 | 16.78 | 13.99 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 100.00% | 0.00% | 0.00% | -50.00% | 200.00% | 33.33% | -25.00% | 0.00% | 233.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 150.00% | -100.00% | 0.00% | -50.00% | 250.00% | -166.67% | -58.33% | 25.00% | 233.33% |
Ambar Protein Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| TTM: | 32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 50% |
| 3 Years: | 29% |
| TTM: | 142% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| 1 Year: | 127% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 23% |
| 3 Years: | 21% |
| Last Year: | 32% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:21 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | -4 | -3 | -1 | 0 | 2 | 4 | 5 | 9 | 13 | 16 | 19 | 29 | 32 |
| Borrowings | 6 | 6 | 8 | 10 | 18 | 24 | 27 | 27 | 33 | 29 | 26 | 26 | 23 |
| Other Liabilities | 5 | 4 | 5 | 7 | 5 | 19 | 11 | 8 | 12 | 11 | 11 | 10 | 10 |
| Total Liabilities | 12 | 13 | 17 | 23 | 31 | 53 | 49 | 50 | 64 | 62 | 61 | 71 | 70 |
| Fixed Assets | 4 | 4 | 6 | 6 | 6 | 7 | 22 | 21 | 21 | 20 | 19 | 18 | 18 |
| CWIP | 0 | 0 | 0 | 0 | 6 | 16 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 8 | 9 | 12 | 17 | 19 | 31 | 27 | 29 | 44 | 42 | 42 | 51 | 52 |
| Total Assets | 12 | 13 | 17 | 23 | 31 | 53 | 49 | 50 | 64 | 62 | 61 | 71 | 70 |
Below is a detailed analysis of the balance sheet data for Ambar Protein Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Reserves, as of Sep 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 23.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 26.00 Cr. (Mar 2025) to 23.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 70.00 Cr.. The value appears to be improving (decreasing). It has decreased from 71.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 1.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 52.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Mar 2025) to 52.00 Cr., marking an increase of 1.00 Cr..
- For Total Assets, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 71.00 Cr. (Mar 2025) to 70.00 Cr., marking a decrease of 1.00 Cr..
Notably, the Reserves (32.00 Cr.) exceed the Borrowings (23.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -4.00 | -6.00 | -7.00 | -15.00 | -20.00 | -21.00 | -19.00 | -24.00 | -22.00 | -19.00 | -10.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 3 | 2 | 3 | 8 | 3 | 2 | 3 | 4 | 10 | 15 | 15 | 18 |
| Inventory Days | 11 | 12 | 18 | 19 | 16 | 37 | 20 | 22 | 32 | 23 | 24 | 20 |
| Days Payable | 13 | 10 | 11 | 9 | 6 | 10 | 3 | 5 | 9 | 7 | 8 | 3 |
| Cash Conversion Cycle | 1 | 4 | 10 | 18 | 13 | 29 | 19 | 21 | 33 | 30 | 31 | 34 |
| Working Capital Days | -8 | -8 | -4 | -1 | -4 | -9 | -8 | -2 | 3 | 4 | 6 | 12 |
| ROCE % | 8% | 28% | 18% | 22% | 17% | 13% | 15% | 18% | 18% | 13% | 13% | 28% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.78 | 5.47 | 4.92 | 7.74 | 6.00 |
| Diluted EPS (Rs.) | 16.78 | 5.47 | 4.92 | 7.74 | 6.00 |
| Cash EPS (Rs.) | 19.06 | 7.75 | 7.11 | 9.97 | 8.09 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 60.39 | 43.60 | 38.13 | 33.21 | 25.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.39 | 43.60 | 38.13 | 33.21 | 25.48 |
| Revenue From Operations / Share (Rs.) | 733.26 | 586.19 | 600.13 | 590.87 | 544.87 |
| PBDIT / Share (Rs.) | 28.89 | 13.72 | 13.50 | 17.18 | 13.61 |
| PBIT / Share (Rs.) | 26.61 | 11.43 | 11.29 | 14.95 | 11.52 |
| PBT / Share (Rs.) | 22.66 | 7.16 | 6.88 | 10.27 | 6.92 |
| Net Profit / Share (Rs.) | 16.78 | 5.47 | 4.89 | 7.74 | 6.00 |
| PBDIT Margin (%) | 3.93 | 2.34 | 2.25 | 2.90 | 2.49 |
| PBIT Margin (%) | 3.62 | 1.95 | 1.88 | 2.53 | 2.11 |
| PBT Margin (%) | 3.09 | 1.22 | 1.14 | 1.73 | 1.27 |
| Net Profit Margin (%) | 2.28 | 0.93 | 0.81 | 1.30 | 1.10 |
| Return on Networth / Equity (%) | 27.79 | 12.54 | 12.83 | 23.30 | 23.54 |
| Return on Capital Employeed (%) | 41.06 | 23.61 | 24.19 | 34.46 | 30.62 |
| Return On Assets (%) | 13.68 | 5.12 | 4.51 | 6.93 | 6.86 |
| Long Term Debt / Equity (X) | 0.00 | 0.01 | 0.07 | 0.14 | 0.24 |
| Total Debt / Equity (X) | 0.74 | 1.02 | 1.34 | 1.72 | 1.86 |
| Asset Turnover Ratio (%) | 6.39 | 5.45 | 5.46 | 5.94 | 6.29 |
| Current Ratio (X) | 1.45 | 1.21 | 1.19 | 1.11 | 1.00 |
| Quick Ratio (X) | 0.83 | 0.61 | 0.63 | 0.42 | 0.39 |
| Inventory Turnover Ratio (X) | 20.84 | 16.08 | 13.93 | 14.65 | 18.92 |
| Interest Coverage Ratio (X) | 7.32 | 3.21 | 3.07 | 3.67 | 2.96 |
| Interest Coverage Ratio (Post Tax) (X) | 5.26 | 2.28 | 2.11 | 2.65 | 2.30 |
| Enterprise Value (Cr.) | 141.53 | 108.01 | 151.38 | 48.68 | 29.74 |
| EV / Net Operating Revenue (X) | 0.33 | 0.32 | 0.43 | 0.14 | 0.09 |
| EV / EBITDA (X) | 8.52 | 13.69 | 19.50 | 4.93 | 3.80 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.24 | 0.35 | 0.05 | 0.01 |
| Price / BV (X) | 3.36 | 3.34 | 5.62 | 0.89 | 0.27 |
| Price / Net Operating Revenue (X) | 0.27 | 0.24 | 0.35 | 0.05 | 0.01 |
| EarningsYield | 0.08 | 0.03 | 0.02 | 0.26 | 0.85 |
After reviewing the key financial ratios for Ambar Protein Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.06. This value is within the healthy range. It has increased from 7.75 (Mar 24) to 19.06, marking an increase of 11.31.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 733.26. It has increased from 586.19 (Mar 24) to 733.26, marking an increase of 147.07.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.89. This value is within the healthy range. It has increased from 13.72 (Mar 24) to 28.89, marking an increase of 15.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.61. This value is within the healthy range. It has increased from 11.43 (Mar 24) to 26.61, marking an increase of 15.18.
- For PBT / Share (Rs.), as of Mar 25, the value is 22.66. This value is within the healthy range. It has increased from 7.16 (Mar 24) to 22.66, marking an increase of 15.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For PBDIT Margin (%), as of Mar 25, the value is 3.93. This value is below the healthy minimum of 10. It has increased from 2.34 (Mar 24) to 3.93, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 3.62. This value is below the healthy minimum of 10. It has increased from 1.95 (Mar 24) to 3.62, marking an increase of 1.67.
- For PBT Margin (%), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 10. It has increased from 1.22 (Mar 24) to 3.09, marking an increase of 1.87.
- For Net Profit Margin (%), as of Mar 25, the value is 2.28. This value is below the healthy minimum of 5. It has increased from 0.93 (Mar 24) to 2.28, marking an increase of 1.35.
- For Return on Networth / Equity (%), as of Mar 25, the value is 27.79. This value is within the healthy range. It has increased from 12.54 (Mar 24) to 27.79, marking an increase of 15.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 41.06. This value is within the healthy range. It has increased from 23.61 (Mar 24) to 41.06, marking an increase of 17.45.
- For Return On Assets (%), as of Mar 25, the value is 13.68. This value is within the healthy range. It has increased from 5.12 (Mar 24) to 13.68, marking an increase of 8.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.74. This value is within the healthy range. It has decreased from 1.02 (Mar 24) to 0.74, marking a decrease of 0.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 6.39. It has increased from 5.45 (Mar 24) to 6.39, marking an increase of 0.94.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.45, marking an increase of 0.24.
- For Quick Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.83, marking an increase of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 20.84. This value exceeds the healthy maximum of 8. It has increased from 16.08 (Mar 24) to 20.84, marking an increase of 4.76.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.32. This value is within the healthy range. It has increased from 3.21 (Mar 24) to 7.32, marking an increase of 4.11.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.26. This value is within the healthy range. It has increased from 2.28 (Mar 24) to 5.26, marking an increase of 2.98.
- For Enterprise Value (Cr.), as of Mar 25, the value is 141.53. It has increased from 108.01 (Mar 24) to 141.53, marking an increase of 33.52.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.33, marking an increase of 0.01.
- For EV / EBITDA (X), as of Mar 25, the value is 8.52. This value is within the healthy range. It has decreased from 13.69 (Mar 24) to 8.52, marking a decrease of 5.17.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
- For Price / BV (X), as of Mar 25, the value is 3.36. This value exceeds the healthy maximum of 3. It has increased from 3.34 (Mar 24) to 3.36, marking an increase of 0.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ambar Protein Industries Ltd:
- Net Profit Margin: 2.28%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 41.06% (Industry Average ROCE: 14.31%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 27.79% (Industry Average ROE: 12.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.26
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.83
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 16.9 (Industry average Stock P/E: 149.8)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.74
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.28%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Edible Oils & Solvent Extraction | Block No. 351p2, 353p2 and 358, Panchratna Estate, Ahmedabad District Gujarat 382213 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradeep C Khetani | Managing Director |
| Mr. Jayprakash J Vachhani | Whole Time Director |
| Mr. Shirishkumar D Patel | Director |
| Mr. Bharatbhai D Patel | Director |
| Mr. Dashrathbhai A Patel | Director |
| Mrs. Shobhanaben J Vachhani | Director |
| Mr. Gangaram Bhanjibhai Patel | Independent Director |
| Mr. Yogen Pranjivandas Patel | Independent Director |
| Mr. Narottam Chaturdas Tanna | Independent Director |
FAQ
What is the intrinsic value of Ambar Protein Industries Ltd?
Ambar Protein Industries Ltd's intrinsic value (as of 07 January 2026) is ₹290.42 which is 22.54% higher the current market price of ₹237.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹136 Cr. market cap, FY2025-2026 high/low of ₹433/168, reserves of ₹32 Cr, and liabilities of ₹70 Cr.
What is the Market Cap of Ambar Protein Industries Ltd?
The Market Cap of Ambar Protein Industries Ltd is 136 Cr..
What is the current Stock Price of Ambar Protein Industries Ltd as on 07 January 2026?
The current stock price of Ambar Protein Industries Ltd as on 07 January 2026 is ₹237.
What is the High / Low of Ambar Protein Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ambar Protein Industries Ltd stocks is ₹433/168.
What is the Stock P/E of Ambar Protein Industries Ltd?
The Stock P/E of Ambar Protein Industries Ltd is 16.9.
What is the Book Value of Ambar Protein Industries Ltd?
The Book Value of Ambar Protein Industries Ltd is 65.2.
What is the Dividend Yield of Ambar Protein Industries Ltd?
The Dividend Yield of Ambar Protein Industries Ltd is 0.00 %.
What is the ROCE of Ambar Protein Industries Ltd?
The ROCE of Ambar Protein Industries Ltd is 27.5 %.
What is the ROE of Ambar Protein Industries Ltd?
The ROE of Ambar Protein Industries Ltd is 32.3 %.
What is the Face Value of Ambar Protein Industries Ltd?
The Face Value of Ambar Protein Industries Ltd is 10.0.